CA2200629A1 - Adenoviraux comprenant deux genes therapeutiques: suicide et immunostimulant - Google Patents

Adenoviraux comprenant deux genes therapeutiques: suicide et immunostimulant

Info

Publication number
CA2200629A1
CA2200629A1 CA002200629A CA2200629A CA2200629A1 CA 2200629 A1 CA2200629 A1 CA 2200629A1 CA 002200629 A CA002200629 A CA 002200629A CA 2200629 A CA2200629 A CA 2200629A CA 2200629 A1 CA2200629 A1 CA 2200629A1
Authority
CA
Canada
Prior art keywords
gene
adenovirus
genes
adenoviruses
adenovirus according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002200629A
Other languages
English (en)
French (fr)
Inventor
Michel Perricaudet
Patrice Denefle
Bruno Tocque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centelion SAS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2200629A1 publication Critical patent/CA2200629A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002200629A 1994-10-04 1995-10-02 Adenoviraux comprenant deux genes therapeutiques: suicide et immunostimulant Abandoned CA2200629A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR94/11846 1994-10-04
FR9411846A FR2725213B1 (fr) 1994-10-04 1994-10-04 Vecteurs viraux et utilisation en therapie genique

Publications (1)

Publication Number Publication Date
CA2200629A1 true CA2200629A1 (fr) 1996-04-11

Family

ID=9467551

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002200629A Abandoned CA2200629A1 (fr) 1994-10-04 1995-10-02 Adenoviraux comprenant deux genes therapeutiques: suicide et immunostimulant

Country Status (9)

Country Link
EP (1) EP0784691A1 (es)
JP (1) JPH10506289A (es)
AU (1) AU714867B2 (es)
CA (1) CA2200629A1 (es)
FI (1) FI971377A0 (es)
FR (1) FR2725213B1 (es)
MX (1) MX9702078A (es)
NO (1) NO319893B1 (es)
WO (1) WO1996010642A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08509606A (ja) * 1993-04-20 1996-10-15 ロビンソン，ウィリアム エス． 細胞内感染因子に感染した個体を処置する方法および物質
US6593456B1 (en) 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
DE69840524D1 (de) * 1997-08-13 2009-03-19 Uab Research Foundation Impfung durch topische verwendung genetischer vektoren
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US7041654B2 (en) 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US6087164A (en) * 1997-10-03 2000-07-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
US7569217B2 (en) 2001-09-24 2009-08-04 University Of Saskatchewan Porcine adenovirus E1 and E4 regions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE132534T1 (de) * 1986-08-01 1996-01-15 Commw Scient Ind Res Org Rekombinanter impfstoff
WO1993010218A1 (en) * 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
AU675948B2 (en) * 1992-05-01 1997-02-27 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Bystander effect tumoricidal therapy
AU680459B2 (en) * 1992-12-03 1997-07-31 Genzyme Corporation Gene therapy for cystic fibrosis
FR2704234B1 (fr) * 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
JP3532566B2 (ja) * 1993-06-24 2004-05-31 エル． グラハム，フランク 遺伝子治療のためのアデノウイルスベクター
FR2707664B1 (fr) * 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2712603B1 (fr) * 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.

Also Published As

Publication number Publication date
EP0784691A1 (fr) 1997-07-23
AU3611495A (en) 1996-04-26
NO971521D0 (no) 1997-04-03
FR2725213B1 (fr) 1996-11-08
JPH10506289A (ja) 1998-06-23
FI971377A (fi) 1997-04-03
WO1996010642A1 (fr) 1996-04-11
MX9702078A (es) 1997-06-28
AU714867B2 (en) 2000-01-13
NO971521L (no) 1997-04-03
FR2725213A1 (fr) 1996-04-05
NO319893B1 (no) 2005-09-26
FI971377A0 (fi) 1997-04-03

Similar Documents

Publication Publication Date Title
EP0695360B1 (fr) Adenovirus recombinants defectifs pour la therapie genique des tumeurs
FR2712603A1 (fr) Virus recombinants, préparation et utilisation en thérapie génique.
EP0698108B2 (fr) Vecteurs adenoviraux d'origine animale et utilisation en therapie genique
EP0667912B1 (fr) Vecteurs adenoviraux defectifs et utilisation en therapie genique
EP0719332B1 (fr) Cellules recombinantes de la lignee monocyte-macrophage pour la therapie genique
KR102150027B1 (ko) 종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이
FR2725726A1 (fr) Vecteurs viraux et utilisation en therapie genique
FR2766091A1 (fr) Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2688514A1 (fr) Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
CA2234263C (fr) Composition pharmaceutique contre les tumeurs et infections a papillomavirus
EP0729516A1 (fr) Adenovirus recombinants pour la therapie genique des cancers
CA2211039C (fr) Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
CA2200629A1 (fr) Adenoviraux comprenant deux genes therapeutiques: suicide et immunostimulant
FR2724945A1 (fr) Vecteurs viraux et utilisation en therapie genique
EP1002120B1 (fr) Vecteurs adenoviraux chimeres
MXPA97002078A (es) Adenovirus que comprenden dos genes terapeuticos:suicida e inmunoestimulante
CA2158869C (fr) Virus recombinants, preparation et utilisation en therapie genique
WO2011101912A1 (ja) 組み換えヘルペスウイルス及び組換えヘルペスウイルスを含む医薬組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead